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Diet and the central neyvous system 89 I n some patients deprived of milk or other galactose-containing food from birth, the intelligence nevertheless remains low, suggesting some prenatal damage to the brain. Coupled with this is the finding by I-Isia & Walker (1961) that the birth weights of galactosaemic infants were less than those of their unaffected siblings and that the death rate was still high in infancy cven with treatment from birth. Galactose-1 -phosphate, the probable toxic substance in galactosaemia, does not pass readily through cell membranes and remains or is metabolized in the cell in which it is formcd. Thus, if a foetus lacks the transferase and galactose is circulating in the maternal blood, the galactose will cross the placenta, enter the foetal cells and accumulate there as galactose-1-phosphate (Schwarz, 1960) . It is advisable, therefore, to give the mother of a galactosaemic infant a galactose-free diet during subsequent pregnancies.
Screening the newborn. It has been recommended that all newborn infants be tested for galactosaemia so that, where necessary, treatment can be startcd at the earliest possible moment. Sirlcc the prevalence of galactosaemia is only I in 70 000 live births, such screening programmes are usually set up in conjunction with screening for phenylketonuria and other inborn errors of metabolism. Galactose is sought in urine or blood, either by chromatography or microbiological assay. In a recent method, Beutler, Baluda 8r: Donne11 (1964) describe a simple direct test for the enzyme galactose-1 -phosphate uridylyltransferase, that can be carried out on cord blood; this may well be the screening method of choice for galactosaemia.
Genetics. Direct assay of transferase in the red blood cells shows that about half of all galactosaemics have no detectable transferase activity and the other half have between 3 and 1z0/, of normal enzyme activity. There seems to be little or no correlation between the level of this residual activity and the degree of clinical severity. A difficulty of interpretation of enzyme assays is that we do not know how closely the enzyme content of erythrocytes corresponds to that of liver cells in different individuals. This is made evident by the existence of symptomless heterozygotes with transferase levels in their red cells in the galactosaemic range, of heterozygotes with apparently normal enzyme levels but marked intolerance to galactose and of individuals with all the clinical and biochemical features of galactosaemia except for normal enzyme levels in their red cells (Woolf, 1962a) .
Beutlcr, Baluda, Sturgeon & Day (196;) described the Duarte variant, a gene that, in the homozygous state, causes the transferasc level in thc red cell to be about half normal. The simplest explanation is that this genc is allelic with the galactosaemia gene and the normal gene coded for the transferase and that the Duarte gene codes for a less efficient variant of the enzyme. There may be a large number of different alleles at this locus, some, like the Duarte gene, without perceptible clinical effect.
Alternative pathways of galactose metabolism. When [I -14C]galactose is administered to most galactosaemics, the I4CO, content of their expired air is, on the average, 13% of normal. This indicates that pathways for galactose metabolism exist independent of the transferase ; some of these alternative pathways have been worked out.
SYMPOSIUM PROCEEDINGS
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Segal and his co-workers have described a select group of patients presenting in infancy with typical symptoms of galactosaemia and with no transferase in their red cells who can metabolize labelled galactose to lQCO, as fast as normal individuals (Segal, Blair & Roth, 1965) . Family studies showed that some clinically unaffected siblings of these patients also lacked trarisferase yct could metabolize galactose at the normal rate. All these individuals are negroes and the condition has been termed the 'negro variant' of galactosaemia. It seems probable that the enzyme catalysing one of the alternative pathways of galactose metabolism is present in much greater amount in some populations than in others, because of gene variation.
Galac to k inase deficiency Gitzelmann (1965) has recently described a new inborn error of galactose metabolism-absence of galactokinase. T h e galactose content of blood and urine was as high as in galactosaemia, but the blood had no galactose-I -phosphate. Clinically, the patient suffered from cataracts but was otherwise well, of normal intelligence and without liver disease. This condition has been termed the 'Swiss-variant of galactosaemia' .
Phenylketonziria
Biochemistry. NormalIy the first step in phenylalanine metabolism is oxidation to tyrosine, a reaction catalysed by phenylalanine 4-hydroxylase. I n phenylketonuria, discovered by Folling (1934) , this enzyme is absent or inactive and phenylalanine therefore accumulates. T h e high concentration of phenylalanine in the tissues causes reactions such as transamination, decarboxylation and acetylation to proceed at appreciable rates; normally these reactions make a negligible contribution to the metabolism of phenylalanine. T h c direct and indirect products of these reactions, so-called 'abnormal' metabolites such as phenylpyruvic acid, phenylacetylglutamine and o-hydroxyphenylacetic acid, are excreted in the urine.
Clinical features. Typically, phenylketonuria is characterized by profound mental retardation after a few months of age, though the patients are normal at birth. T h e majority of older phenylketonurics have an IQ below 30. Many show disturbances of behaviour that may approach the psychotic. At least 90% show abnormalities of the electroencephalogram (EEG) and Z O -Z~ Changes in the brain. Using histological techniques, deficient myelination in some cases of phenylketonuria has been reported (Crome & Pare, 1960; Jervis, 1963) . Chemical estimation of myelin lipids has revealed a marked deficiency in the white matter of the brain, even in some cases considered normal by histological examination (Crome, Tymms & Woolf, 1962) . It seems clear that phenylalanine or its 'abnormal' metabolites, or both, hinder the deposition of myelin in the brain; it is not known whether this leads to mental retardation, etc. or whether the morphological change and mental and neurological features are different effects of a common cause, but there can be no doubt that they are related. Phenylalanine and/or some of its 'abnormal' metabolites inhibit enzymes essential for the production of the synaptic transmitters dopamine, noradrenaline, serotonin and y-aminobutyric acid (Fellman, 1956; Davison & Sandler, 1958; Hanson, 1959; Roylen & Quastel, 1961 ; Tashian, 1961 ; McKean, Schanberg & Giarman, 1962) . This reduction in neurohormone production should be rapidly reversible when the concentration of phenylalanine falls and may account for the dramatically rapid improvement in seizure frequency, EBG and behaviour often seen when an older phenylketonuric is first given a low-phenylalanine diet. The inyelin deficiency may account for the irreversible component of the mental retardation.
Treatment. I n 1951 the theory was put forward that the mental and neurological features characteristic of phenylketonuria were the result of intoxication by phenylalanine or its 'abnormal' metabolites and could be prevented or ameliorated by a diet low in phenylalanine (Woolf & Vulliamy, 1951 ). An economic form of such a diet was devised (Woolf, Griffiths & Moncrieff, 1955) and has now been given to several hundred phenylketonurics. T h e results of such treatment from earliest infancy are: normal or nearly normal IQ, absence of epileptic seizures, normal EEG and normal, non-psychotic hehaviour (Woolf, or essential fatty acids might account for the lesions, but this now seems unlikely. These unintentional experiments have demonstrated that phenylalanine is an essential amino acid for the human infant and that treatment requires careful biochemical control.
I n some cases treated phenylketonurics have returned to a normal diet after a few years. When treatment has started relatively late, there is often a rapid deterioration to the state before treatment started. Some phenylketonurics, treated from very early infancy, do not appear to deteriorate if they are returned to a normal diet after a few years, but it is possible that very slow detcrioration, detectable over several years, occurs even here (I T h e liver, both in hyperphenylalaninaemia and in atypical phenylketonuria, contains appreciable phenylalanine hydroxylase activity though far less than in the normal, Maternal phenylketonuria. A few phenylketonuric women have given birth, the offspring being, in general, non-phenylketonuric. In some cases the children were normal ), in others they were moderately retarded (Mabry, Denniston & Coldwell, 1966) . T h e intelligmce of the offspring appears to be inversely correlated with the concentration of phenylalanine in the maternal blood. It appears that the foetal brain can be damaged to some extent by exposure to a phenylketonuric milieu in utero if the concentrations are high enough. Women with phenylketonuria should be treated with a diet low in phenylalanine throughout pregnancy, aiming to keep the blood phenylalanine level below 10 mg/Ioo ml. This applies, of course, to any successfully treated female phenylketonuric whose dietary treatment has been relaxed.
Screening programmes. For optimum results dietary treatment must be started in earliest infancy, long before any clinical signs are manifest and when phenylketonuria can be diagnosed only by chemical tests (Woolf et al. 1958 ). I t follows that the whole population of newborn infants must be screened by appropriate tests. This is now being done in many countries, including Great Britain. In Southern Ireland and in Glasgow a prevalence of I phenylketonuric in every 4000 live births is being found (J. Scott, 1967, personal cotnniunication; Cahalane, 1968) in close agreement with the calculated figure (Carter & Woolf, 1961) . I n the USA a prevalence of I in 10 ooo is found; about one-third of these have hyperphenylalaninaemia rather than plienylketonuria, but even allowing for this there is a discrepancy with the figure I in 20 ooo based on surveys of institutions for the 93 Vol. 27
Diet and tlze central nervous system retarded (MacCready, I 967). Critics of the effects claimed for dietary treatment point to this discrepancy and suggest that half of all 'phenylketonurics' would not be mentally retarded even if untreated; they suggest that treatment may appear to be efficacious only in those who would have been normal without treatment (Bessman, 1966) . This seems unlikely on several grounds. ( I ) Statistical : the number of phenylketonurics successfully treated from early infancy is too high for it to be probable that all of them fall in this 'unaffected' group.
( 2 ) Genetic: the variant forms of phenylketonuria run fairly true to type within sibships, but some successfully treated phenylketonurics have untreated older sibs who are very severely affected.
(3) Clinical : the older, clinically affected, phenylketonuric child often shows marked neurological improvement on a low-phenylalanine diet.
Homocystinu yia
Homocystinuria was first described by Carson & Neil1 (1962) Biochemistry. Methionine is normally demethylated to homocysteine which reacts with serine to form cystathionine, a reaction catalysed by the enzyme cystathionine synthetase. Cystathionine is then converted into cysteine which is in equilibrium with cystine. I n hoinocystinuria the enzyme cystathionine synthetase is absent or virtually inactive and homocysteine therefore accumulates in the blood and tissues where it is in equilibrium with the disulphide form-homocystine. Much homocysteine is methylated to methionine which reaches high concentrations in the tissues and body fluids.
Cystathionine is normally present in highest concentration in parts of the brain and it may be necessary for normal activity of nerve cells. Homocystinurics lack cystathionine synthetase and, in the two patients examined, the brain contained very little cystathionine. It is not known whether the clinical features of homocystinuria result from a toxic excess of homocysteine or of methionine, or of both, or from a deficiency of cystathionine. It is not practicable to increase the cystathionine content of the brain-if this very expensive amino acid were fed it would be rapidly excreted in the urine. It is in any event difficult to believe that so many homocystinurics would be of normal or nearly normal intelligence if, lacking cystathionine as they do, this amino acid were essential for normal brain function. However, it is possible that though cystathionine synthetase is absent from the liver in all cases and from the brain in some, this enzyme (or an isozyme) occurs in the brain in some homocystinurics ; cystathionine synthetase has been found in the lens of the eye in one patient (Gaull, 1967) .
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